VIM
PCRX icon

Vinva Investment Management’s Pacira BioSciences PCRX Stock Holding History

Vinva Investment Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
27,587
+21,013
+320% +$497K 0.01% 342
2026
Q1 		$223K Buy
+6,574
New +$146K ﹤0.01% 432

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vinva Investment Management's PCRX Position: Q2 2026 in Review

Vinva Investment Management increased its Pacira BioSciences (PCRX) stake by 320% in Q2 2026, buying an estimated $497K and bringing the position to 27,587 shares worth $1.01M. The position accounts for 0.01% of the portfolio, ranked #342.

Vinva Investment Management first reported a position in PCRX in Q1 2026 and has held it in 2 quarters since. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Vinva Investment Management held 27,587 shares of Pacira BioSciences worth $1.01M as of Q2 2026.
  • Vinva Investment Management bought 21,013 Pacira BioSciences shares in Q2 2026, an estimated $497K.
  • Pacira BioSciences made up 0.01% of Vinva Investment Management's portfolio in Q2 2026, its #342 holding.
  • Vinva Investment Management first reported a position in Pacira BioSciences in Q1 2026 and has held it in 2 quarters since.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Vinva Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.